<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03883347</url>
  </required_header>
  <id_info>
    <org_study_id>107/13-02-2019</org_study_id>
    <nct_id>NCT03883347</nct_id>
  </id_info>
  <brief_title>Sedation With Dexmedetomidine Versus Remifentanil in Urogynecological Surgery Under Spinal Anaesthesia</brief_title>
  <official_title>Sedation With Dexmedetomidine Versus Remifentanil in Urogynecological Surgery Under Spinal Anaesthesia : Impact on Block Characteristics, on Acute and Chronic Postoperative Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Athens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuraxial blocks are usually used as an anaesthetic method for urogynecological surgeries. In
      most patients under regional anaesthesia, premedication is given for reducing anxiety.
      Purpose of this prospective double blind randomised clinical trial is the investigation of
      the effect of perioperative intravenous infusion of dexmedetomidine vs remifentanil for
      sedation in patients under spinal anaesthesia for urogynecological procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The day before surgery the procedure will be explained to the patient and the written consent
      will be obtained. In the operating room, intraoperative monitoring will include ECG,
      noninvasive blood pressure, oxygen saturation by pulse oximetry (SpO2) and heart rate (HR). A
      peripheral intravenous catheter wil be placed for fluid replacement ( Ringer's Lactate
      solution 6 - 8ml/ kg/hr) and administration of drugs.

      Women will be randomly assigned into one of two groups:

      Group A: Women will receive dexmedetomidine continuously infused at a dose of 0,6 mcg/kg for
      10 minutes (concentration of the solution 6mcg/ml) before spinal anaesthesia. Infusion will
      be stopped in order to proceed with regional anesthesia.

      Group B: Women will receive remifentanil continuously infused at a dose of 1mcg/kg for 10
      minutes (concentration of the solution 1mcg/ml) before spinal anaesthesia. Infusion will be
      stopped in order to proceed with regional anesthesia.

      The insertion of a 27 Gauge (27G) spinal needle is performed at L3-L4 or L4-L5 interspace, in
      the lateral position. All patients will receive 2,7 ml ropivacaine 0,75% and 15 mcg fentanyl
      intrathecally and assessment of sensory and motor block will be assessed every 2 min. The
      moment that sensory block is in the highest dermatome and motor block is complete (Bromage
      grade 3) is Time to max effect (Tmax). In group A an infusion of dexmedetomidine (6mcg/ml) at
      a dose of 0,6mcg/kg/hr will be administered and in group B an infusion of remifentanil
      (1mcg/ml) at a dose of 0,03 mcg/kg/min.At the end of the surgery patients will be transferred
      in Post Anaesthetic Care Unit (PACU) and a patient control analgesia (PCA) pump will be
      provided to the patient, administering 1 mg of morphine in every attempt, with a lock out
      interval of 10 minutes.There will be no continuous infusion. All patients will receive a
      standardized multimodal approach, including diclofenac 50 mg t.i.d, paracetamol 1gr as rescue
      analgesia (max 4 gr per day) and PCA with morphine.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2019</start_date>
  <completion_date type="Anticipated">April 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>All syringes and solutions will be prepared by an independent researcher who will not be further involved in the study eg data collecting or analyzing them.All syringes will look identical to the anesthetist who will administer them to the patients.Apart from the anesthetist, the surgery staff and the researchers recording the measurements will not know the therapeutic intervention team in which each patient has been randomized.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of postoperative analgesia</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Time for first analgesia / PCA first bolus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analgesic consumption</measure>
    <time_frame>0 hours, 2 hours, 4 hours, 8 hours, 24 hours postoperatively</time_frame>
    <description>Morphine consumption in mg</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>0 hours, 2 hours, 4 hours, 8 hours, 24 hours postoperatively</time_frame>
    <description>Numerical Rating Scale (NRS scale) (0:no pain 10:worst pain ever)</description>
  </other_outcome>
  <other_outcome>
    <measure>Chronic pain</measure>
    <time_frame>6 months</time_frame>
    <description>Using of Graded Chronic Pain Scale (GCPS) Grade 0: No pain in prior 6 months Grade 1: Low Intensity - Low Disability Grade II: High Intensity Characteristic Pain Intensity - Low Disability Grade III: High Disability - Moderately Limiting Grade IV: High Disability - Severely Limiting</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse effects</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Adverse effects of drugs, anaesthetic or surgical technique and any intraoperative adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>Sedation</measure>
    <time_frame>0 hours, 2 hours, 4 hours, 8 hours, 24 hours postoperatively</time_frame>
    <description>Ramsay sedation scale ( 1:anxious, agitated or restless- 6: asleep, no response )</description>
  </other_outcome>
  <other_outcome>
    <measure>Postoperative need of rescue analgesia</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Consumption of paracetamol</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient satisfaction over anaesthesia</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>scale for satisfaction (0:no satisfaction at all, 10:satisfaction)</description>
  </other_outcome>
  <other_outcome>
    <measure>Nausea</measure>
    <time_frame>0 hours, 2 hours, 4 hours, 8 hours, 24 hours postoperatively</time_frame>
    <description>Scale for nausea (0:no nausea 10:worst possible nausea)</description>
  </other_outcome>
  <other_outcome>
    <measure>Vomiting</measure>
    <time_frame>0 hours, 2 hours, 4 hours, 8 hours, 24 hours postoperatively</time_frame>
    <description>Number of vomits</description>
  </other_outcome>
  <other_outcome>
    <measure>Sedation</measure>
    <time_frame>Baseline (before start of infusion), at 5 minutes load, end of 10 minutes load, at spinal time, every 5 minutes until 30 minutes, every 10 minutes until the end of the surgery</time_frame>
    <description>Ramsay sedation scale(1:anxious, agitated or restless- 6: asleep, no response)</description>
  </other_outcome>
  <other_outcome>
    <measure>Sensory blockade</measure>
    <time_frame>30 minutes</time_frame>
    <description>Time for onset of sensory block at T10 and to maximum sensory block</description>
  </other_outcome>
  <other_outcome>
    <measure>Motor blockade</measure>
    <time_frame>30 minutes</time_frame>
    <description>Time to bromage 2 and to bromage 3</description>
  </other_outcome>
  <other_outcome>
    <measure>Highest level of sensory block</measure>
    <time_frame>30 minutes</time_frame>
    <description>dermatome</description>
  </other_outcome>
  <other_outcome>
    <measure>Sensory Regression</measure>
    <time_frame>240 minutes</time_frame>
    <description>Time to two segment regression</description>
  </other_outcome>
  <other_outcome>
    <measure>Motor block regression</measure>
    <time_frame>240 minutes</time_frame>
    <description>time to bromage 1 and bromage 0</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to max effect (Tmax)</measure>
    <time_frame>30 minutes</time_frame>
    <description>Time when the motor blockade is complete and sensory blockade is in the highest dermatome</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Vaginal Hysterectomy</condition>
  <condition>Suburethral Slings</condition>
  <arm_group>
    <arm_group_label>Group DEX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous administration of dexmedetomidine 0.6 mcg / kg within 10 minutes prior to regional anesthesia. The infusion of the solution will be discontinued and then will be performed in all patients subarachnoid anesthesia. Starting with Tmax, infusion of the solution will be initiated again at a dose of 0.6 mcg / kg / h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group REMI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous administration of remifentanil 1 mcg / kg within 10 minutes prior to regional anesthesia. The infusion of the solution will be discontinued and then will be performed in all patients subarachnoid anesthesia. Starting with Tmax, infusion of the solution will be initiated again at a dose of 0.025 mcg / kg / min.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Intravenous administration of dexmedetomidine 0.6 mcg / kg within 10 minutes prior to regional anesthesia and 0.6 mcg / kg / h after performing regional anaesthesia until the end of the surgery</description>
    <arm_group_label>Group DEX</arm_group_label>
    <other_name>DEXDOR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Intravenous administration of remifentanil 1 mcg / kg within 10 minutes prior to regional anesthesia and 0.025 mcg / kg / h after performing regional anaesthesia until the end of the surgery</description>
    <arm_group_label>Group REMI</arm_group_label>
    <other_name>ULTIVA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Physical status according to American Society of Anesthesiologists (ASA) I-II

          -  Patients scheduled for transvaginal urogynecological or gynecological surgery

        Exclusion Criteria:

          -  Patient refusal

          -  Contraindication of spinal anaesthesia (Coagulopathy, Local infection at the site of
             injection, Local anaesthetic allergy, Hypovolaemia)

          -  BMI &gt; 30 kg/m2

          -  Personal history of cardiovascular disease

          -  Arrythmias

          -  Conduction disorders

          -  Severe kidney or liver dysfunction

          -  Insulin-dependent diabetes mellitus

          -  Central nervous system disorders

          -  Psychiatric and mental status disorders

          -  Chronic Excessive Alcohol Consumption

          -  Chronic Use of Opioid Analgesics

          -  Chronic Use of corticosteroids

          -  Chronic Use of clonidine (or other a2 adrenergic agonist)

          -  Use of drugs acting on central nervous system or analgetics the last two weeks

          -  Communication problems due to language barriers or unable to understand the pain scale
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cryssoula Staikou</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aretaieio Hospital Medical School University of Athens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Panagiota Brattou</last_name>
    <phone>+306957786459</phone>
    <email>brattoup@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chryssoula Staikou</last_name>
    <phone>+306932352742</phone>
    <email>c_staikou@yahoo.gr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aretaieio Hospital, University of Athens</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chryssoula V Staikou, MD</last_name>
      <phone>+210 7286172</phone>
      <email>c_staikou@yahoo.gr</email>
    </contact>
    <investigator>
      <last_name>Chryssoula V Staikou, MD, DESA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 18, 2019</study_first_submitted>
  <study_first_submitted_qc>March 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2019</study_first_posted>
  <last_update_submitted>October 9, 2019</last_update_submitted>
  <last_update_submitted_qc>October 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Athens</investigator_affiliation>
    <investigator_full_name>Staikou Chryssoula</investigator_full_name>
    <investigator_title>Assistant Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

